Insider Buying: IRIDEX (NASDAQ:IRIX) Major Shareholder Acquires $58,000.00 in Stock

Posted by Francis Steltz on Oct 10th, 2026

IRIDEX Corporation (NASDAQ:IRIX – Get Free Report) major shareholder Shih-Yao David Lin acquired 50,000 shares of the company’s stock in a transaction on Monday, May 12th. The shares were bought at an average price of $1.16 per share, for a total transaction of $58,000.00. Following the completion of the purchase, the insider owned 248,348 shares in the company, valued at approximately $288,083.68. This represents a 25.21% increase in their position. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

IRIDEX Price Performance

NASDAQ IRIX opened at $0.89 on Friday. IRIDEX Corporation has a 1 year low of $0.61 and a 1 year high of $1.65. The firm has a market cap of $15.64 million, a price-to-earnings ratio of -4.45 and a beta of 0.67. The company has a fifty day moving average price of $0.73 and a 200-day moving average price of $0.95.

IRIDEX (NASDAQ:IRIX – Get Free Report) last announced its earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.06). The firm had revenue of $12.57 million for the quarter, compared to the consensus estimate of $13.59 million. On average, research analysts anticipate that IRIDEX Corporation will post -0.12 EPS for the current fiscal year.

Hedge Funds Weigh In On IRIDEX

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Bank of New York Mellon Corp purchased a new stake in IRIDEX during the second quarter worth about $29,000. Diversify Advisory Services LLC purchased a new position in IRIDEX in the second quarter valued at about $30,000. Diversify Wealth Management LLC purchased a new position in IRIDEX in the first quarter valued at about $35,000. United Capital Financial Advisors LLC bought a new position in shares of IRIDEX during the 2nd quarter valued at approximately $41,000. Finally, Thompson Davis & CO. Inc. grew its position in shares of IRIDEX by 66.5% during the 1st quarter. Thompson Davis & CO. Inc. now owns 47,444 shares of the medical equipment provider’s stock valued at $48,000 after acquiring an additional 18,944 shares during the period. 20.10% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Weiss Ratings raised IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 2nd. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, IRIDEX currently has a consensus rating of “Hold” and an average price target of $3.00.

Check Out Our Latest Research Report on IRIX

About IRIDEX

(Get Free Report)

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.